Activella

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Activella

Property Description
Active Ingredients Estradiol, Norethisterone Acetate
Form Oral Film-coated Tablet
Pharmacological Class Sex Hormone Combinations (HRT)
Regimen Type Continuous Combined
Origin Endogenous-identical (Estradiol), Synthetic (Norethisterone Acetate)

What Type of Medicine is Activella?

Activella is a specific brand of medication manufactured by Novo Nordisk, classified as a Sex Hormone Combination used in Hormone Replacement Therapy (HRT). It delivers the two hormones Estradiol and Norethisterone Acetate in a single oral tablet. This formulation provides continuous combined HRT, a regimen where both hormonal components are administered daily without interruption, which is the established standard for combination therapy. This approach is clinically recognized for simplifying the patient's daily routine compared to sequential administration methods.

The drug entity, generically known as estradiol and norethindrone acetate, is intended for oral administration. Its prescription-only status and tablet form differentiate it from generic alternatives like Lopreeza and other combined delivery methods such as transdermal patches.

Composition: A Combination of Estradiol and Norethisterone Acetate

The active core of Activella is its dual composition. The estrogen component, Estradiol, is chemically identical to the most potent endogenous estrogen naturally produced in the body, while Norethisterone Acetate is a synthetic derivative belonging to the progestin class of hormones. The combination in the tablet is designed to ensure stability and reliable systemic absorption upon oral administration.

The combination of these two specific substances is intentional. The necessity of progestin when using estrogen replacement is well-established for patients with an intact uterus. This confirms the structural integrity of the medicine, ensuring that the progestin compound is present to provide necessary protection alongside the estrogen replacement.

General Purpose: Hormone Replacement and Balance

The general purpose of this therapy is to provide effective hormone replacement to the body to stabilize key physiological functions. The medication achieves this through the dual action where Estradiol provides the replacement component to supplement declining estrogen levels, and Norethisterone Acetate provides the necessary balancing progestogenic effect. This treatment is typically directed at women in the postmenopausal phase whose bodies are producing insufficient hormones.

Regulatory References

  1. Estrogen and Progestin (Hormone Replacement Therapy): MedlinePlus Drug Information

What side effects are possible with Activella?

Possible Side Effects and Safety Information

The safety profile of Activella (Estradiol and Norethindrone Acetate) is formally documented in government regulatory labeling, grouping adverse reactions by frequency and physiological system. The most Very Common (ge 10% incidence) side effects reported in clinical trials include headache, nausea, and upper respiratory tract infection. Other common reactions, observed in 1% to 10% of users, include back pain, breast pain, insomnia, and vaginal hemorrhage.


Serious Adverse Reactions and Safety Warnings

Regulatory authorities emphasize that the use of combined estrogen and progestin therapy is associated with an increased risk of serious adverse events. These include Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction (MI). Additionally, there is a documented increased risk of Invasive Breast Cancer.

Population and Duration-Related Safety

Safety data specifies that women aged 65 and older have an increased risk of developing probable dementia. Risks of thromboembolic events like DVT and stroke are often observed to be highest during the first year of treatment.


Safety Restrictions (Contraindications)

Activella is officially restricted in individuals with specific pre-existing health conditions. Contraindications include a history of or current DVT or PE, known liver impairment or disease, undiagnosed abnormal genital bleeding, and known or suspected breast cancer or other estrogen-dependent tumors. These restrictions ensure the therapy is used within defined safety limitations.

Overdose and Emergency Response

The official regulatory documents state that symptoms following the ingestion of a large dose of Activella (estradiol/norethisterone acetate) are generally not expected to be serious or life-threatening. The clinical profile of an overdose is primarily characterized by certain documented manifestations and requires specific emergency actions.

Overdose Manifestations Regulator-Mandated Actions
Nausea and Vomiting Seek immediate medical attention
Breast Tenderness Contact a poison control center
Abdominal Pain Symptomatic and Supportive treatment
Drowsiness or Fatigue No specific antidote is known

Official Regulatory Statements on Overdose

  • Documented Manifestations: Clinical signs following over-ingestion typically include nausea, vomiting, breast tenderness, abdominal pain, and drowsiness/fatigue. A specific finding that may occur in females after discontinuation of a large dose is withdrawal bleeding. This presentation is the basis for the regulatory classification.
  • Emergency Actions: Individuals are required to seek medical attention or contact a poison control center immediately upon the ingestion of a large dose. This action is mandated regardless of the severity of initial symptoms.
  • Management: Management of overdose is directed toward symptomatic and supportive treatment, as official regulatory information states that no specific antidote is known for this medication.
  • Population Note: Ingestion of large doses by children may cause the same symptoms, specifically including withdrawal bleeding in female children, as noted in the prescribing information.

Therapeutic Uses of Activella

What Activella Treats: Main Uses and Benefits

Activella (estradiol and norethindrone acetate) is an approved medication intended for use in women who have an intact uterus following menopause. It is specifically authorized to help manage certain health changes that occur when the body produces less estrogen.

Quick Facts

  • Relieves moderate to severe episodes of flushing and sweating of the upper body and face (vasomotor symptoms) due to menopause.
  • Addresses moderate to severe symptoms associated with the thinning and drying of vulvar and vaginal tissues (atrophy) due to menopause.
  • Assists in the prevention of bone density reduction (postmenopausal osteoporosis) in individuals considered to be at significant risk for the condition.

This therapy may be considered for the three conditions listed above.

Eligibility and Restrictions for Use

Activella's eligibility is determined by strict rules outlined in government regulatory documents.

Populations Allowed

The medicine is officially approved for use in postmenopausal adult women who have an intact uterus. The combination of hormones in Activella is specifically required for women who have not undergone a hysterectomy.

Absolute Contraindications

Activella is strictly contraindicated (must not be used) in women with a known, suspected, or history of breast cancer or estrogen-dependent neoplasia. Use is also prohibited in women with active or a history of arterial or venous thromboembolic disease, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke, or Myocardial Infarction (MI).

Further absolute contraindications include undiagnosed abnormal genital bleeding, known liver impairment or disease, and known thrombophilic disorders. The medicine is also contraindicated during known or suspected pregnancy.

Specific Restrictions

Use is not indicated for the pediatric population. The medicine is not indicated for the prevention of cardiovascular disease or probable dementia in women aged 65 years or older. Caution and close supervision are required for populations with conditions such as renal dysfunction, Hypertriglyceridemia, or Hypothyroidism.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Activella (estradiol and norethindrone acetate) interaction patterns are primarily defined by documented effects on metabolism and protein binding, as detailed in regulatory documents.

Documented Interaction Categories

Interaction Type Interacting Substances/Conditions
Metabolic Alterations CYP3A4 Inducers and Inhibitors
Protein Binding Thyroid Replacement Therapy (e.g., Levothyroxine)
Formal Restrictions Specific Hepatitis C regimens (e.g., Ombitasvir/Paritaprevir/Ritonavir)

Co-administration with CYP3A4 inducers may result in a decrease in the plasma concentration of both active components, whereas CYP3A4 inhibitors may cause an increase in exposure. Specific drug combinations, including regimens for Hepatitis C, are formally restricted from co-administration due to documented interaction risks.

The estrogen component increases the serum level of Thyroid-Binding Globulin (TBG), a pharmacodynamic effect that may necessitate monitoring and potential adjustment of the dose for co-administered thyroid hormones, such as levothyroxine.

Substance-specific data shows that acute alcohol ingestion may increase circulating estradiol levels, and co-administration with food is documented to alter the absorption profile of norethindrone acetate, specifically reducing its peak concentration (Cmax). Furthermore, the official label notes that poor metabolism in women with hepatic impairment acts as a restriction due to the risk of increased systemic exposure.

Mechanism of Action

Activella is a combination medication containing estradiol, an estrogen, and norethindrone acetate, a progestin. Its mechanism of action is mediated by binding to specific intracellular nuclear receptors within target cells, leading to modulation of gene transcription.

Estradiol functions as an agonist for the nuclear Estrogen Receptor (ER), a DNA-binding protein found in tissues such as the pituitary, hypothalamus, and bone. Upon binding and activation, the ER complex relocates to the nucleus and interacts with Estrogen Response Elements (EREs) on the DNA, which enhances the transcription of adjacent genes. This process ultimately modifies the cellular activity of estrogen-responsive tissues and regulates the pituitary secretion of gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), via a negative feedback loop.

Norethindrone acetate is rapidly converted to its active form, norethindrone. This component acts as an agonist for the Progesterone Receptor (PR), primarily in the female reproductive tract, breast, and central nervous system. By binding to the PR, norethindrone induces cellular differentiation and counterbalances the proliferative action of estrogens on the endometrium, thereby decreasing estrogen receptor levels in the uterine lining and promoting gene products that modulate cellular responses to estrogen signaling.

Dosage and Administration Information

How Activella is Used

Activella is an oral medication administered as a film-coated tablet in a continuous combined regimen, which means one tablet is taken once daily without any scheduled interruption.

Official Dosing and Regimen

The medication is available in two fixed-dose strengths of estradiol and norethindrone acetate. The higher strength provides 1 mg / 0.5 mg, while the lower strength provides 0.5 mg / 0.1 mg of the active components. Regardless of strength, the regimen remains a single tablet once daily.

Prescribing involves the use of the lowest effective dose for the shortest duration consistent with treatment goals, necessitating periodic re-evaluation of continued necessity.

Administration Details and Conditions

The tablet may be taken with or without food as the presence of food does not significantly impact absorption. It is recommended that the tablet be consumed at the same time every day to maintain consistent levels.

Procedurally, if a dose is missed, the tablet should be taken immediately only if the delay is within 12 hours of the usual time. If more than 12 hours have passed, the missed dose must be skipped and the regular schedule resumed. This oral combined formulation is intended for use specifically in women who have an intact uterus.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Activella

Overview of Studies for Activella

This section provides a summary of the clinical trial designs, key outcomes measured, and study populations involved in the research for Activella, without making claims about effectiveness or safety. The research has primarily used short-term, randomized, controlled trials (RCTs) to evaluate the medication's components and longer-term studies to explore bone health outcomes.


Evidence for Use in Managing Moderate to Severe Hot Flashes (Vasomotor Symptoms)

Research has explored the patterns of frequent and intense hot flashes in short-term controlled studies. Research has been applied in studies examining patient-reported experiences by focusing on two main outcomes: the mean number of daily hot flashes (frequency) and the severity or intensity of those episodes. These trials included postmenopausal women with an intact uterus who were experiencing a set minimum number of moderate to severe hot flashes each day.

Studies reported patterns observed in the measurements of frequency and intensity of hot flashes compared to women who received a placebo over the initial weeks of investigation. Research describes measurements of change in the mean daily severity score of VMS over the same short-term duration. Findings describe group patterns of how symptoms evolved, but they do not determine whether an individual will respond similarly.

Long-term outcomes are not fully established based only on the initial VMS trials. Evidence remains limited for how long the observed changes persist after the initial months of use.


Evidence for Use in Treating Vulvar and Vaginal Atrophy

Studies have also examined the effects of Activella's components on the thinning and drying of vulvar and vaginal tissues (atrophy). The research explored symptom axes related to physical discomfort and changes in the tissue itself. This involved monitoring patient-reported outcomes describing perceived discomfort like dryness and painful intercourse, alongside objective biological markers.

Research monitored the patient-reported severity of VVA symptoms compared to baseline over short-term intervals (e.g., 12 weeks). Studies monitored patterns indicating changes in tissue composition and acidity levels that were monitored during the study. Comparative research is limited between this oral combination therapy and local (topical) estrogen-only therapies.


Evidence for the Prevention of Postmenopausal Osteoporosis

The evidence for this indication comes from both intermediate-term controlled studies specific to the combination and long-term, large-scale studies for the hormone replacement therapy (HRT) drug class as a whole. Research examined outcomes related to systemic or functional imbalance by measuring changes in Bone Mineral Density (BMD) at the lumbar spine and hip over periods of two years or more.

Studies monitored patterns observed in the studies related to changes in bone density compared to placebo after two years of observation. Long-term data from the general HRT class described patterns related to the frequency of fractures during extended periods (several years). These findings describe group patterns, not personal outcomes.


What Is Still Uncertain About the Research for Activella

A central limitation is that the follow-up durations were limited for the primary VMS and VVA endpoints, meaning the long-term effects on symptom patterns are not fully established. Comparative research is limited for how this specific combination tablet performs against all other forms of HRT. The evidence varies across studies based on differences in their design and focus. Research provides insight into short-term changes but does not determine the long-term risks or benefits over a decade or more of continuous use.

Frequently Asked Questions (FAQ)

Common questions about Activella (FAQ)


Q: What is the main reason doctors prescribe Activella?

Activella is prescribed primarily to address certain symptoms of menopause. Official product information indicates its use to treat moderate to severe vasomotor symptoms (commonly known as hot flashes) and symptoms of vulvar and vaginal atrophy. It is also indicated for the prevention of postmenopausal osteoporosis.


Q: Is Activella the same as other forms of HRT or estrogen-progestin pills?

Activella is a specific brand of continuous combined hormone replacement therapy (HRT). While it contains an estrogen (estradiol) and a progestin (norethindrone acetate), other HRT products may contain different hormones or administration methods, such as patches or gels. The specific combination and continuous regimen define this product.


Q: How quickly do most people start feeling the effects of Activella?

Studies on the main indications, such as hot flashes, typically measure changes over the first few weeks of use. Official clinical data compares symptom severity over short-term periods. The speed at which an individual notices improvement can vary, but effects are generally reported over a period of weeks to months.


Q: Is it normal to have light bleeding or spotting when first starting Activella?

According to official documentation, vaginal hemorrhage or spotting is a common adverse reaction reported in clinical trials for this type of combined therapy. This is particularly noted during the initial months as the body adjusts to the medication. Official guidance states that patients should consult their healthcare provider regarding bleeding that is prolonged or unusual.


Q: Can Activella help with mood swings and sleep problems during menopause?

The medication is approved for treating vasomotor symptoms and osteoporosis prevention, not mood or sleep disorders directly. However, official information lists both insomnia (trouble sleeping) and mood changes (including mood swings) as adverse reactions associated with its use.


Q: Is there a link between Activella and weight gain, as reported by some users?

Weight gain is listed in official sources as a reported adverse effect associated with the use of estrogen-containing hormone therapy. The official label mentions this adverse effect, and any concerns related to changes in body weight can be discussed with a healthcare professional.


Q: Is Activella considered a form of birth control or contraception?

Activella is officially indicated and approved as a Hormone Replacement Therapy (HRT) intended for postmenopausal symptoms. It is not indicated, approved, or officially relied upon as a method of contraception for the prevention of pregnancy.


Q: Can I take vitamins or herbal supplements while using Activella?

Official sources advise that patients disclose all products being used, including prescription, over-the-counter medicines, vitamins, herbal products, and other supplements. Certain supplements may affect the body’s processing of the hormones in Activella, potentially altering their blood levels.


Q: Can being overweight affect how Activella works in the body?

The official warning section lists obesity as a risk factor for certain serious conditions, such as venous thromboembolism (blood clots). Clinical studies often include body mass index (BMI) as a factor for participant selection, indicating that weight is a consideration in the clinical use of this medication.


Q: What are the inactive ingredients in Activella tablets?

The full list of inactive ingredients for Activella, which can include components like lactose monohydrate and specific film coatings, is detailed in the Description section of the FDA Prescribing Information.


Q: Does Activella affect cholesterol or blood pressure levels?

Official warnings state that the estrogen component can affect the serum level of high-density lipoprotein cholesterol (HDL-C). Additionally, elevated blood pressure is a risk factor or potential adverse reaction that is typically monitored when using hormone therapy.


Q: Can antibiotics make Activella less effective?

Official drug interaction information indicates that some medications, including certain antibiotics, can affect liver enzymes (specifically CYP3A4). These enzymes are responsible for breaking down the hormones in Activella, meaning the concurrent use of some drugs could potentially decrease the amount of hormones in the blood.


Q: Does Activella cause hair loss or changes in hair growth?

Hair loss is a reported adverse effect associated with the use of estrogen and progestin therapy. Official information also indicates that increased hair growth (hirsutism) has been reported in some instances.


Q: Why is annual monitoring or check-ups recommended for people taking Activella?

Official prescribing principles require periodic re-evaluation of continued therapy to ensure it remains the lowest effective dose for the shortest duration consistent with treatment goals. This commonly involves annual monitoring of patient health status due to the risks associated with long-term hormone replacement therapy use.


Q: Can Activella be used to treat early menopause symptoms?

Activella is officially approved for use in postmenopausal adult women for its specified indications. Its safety and efficacy in women with early or premature menopause have not been established in the context of its regulatory approval.


Q: Are there any known issues with taking Activella during travel or different time zones?

Official administration instructions recommend taking the tablet at the same time every day to maintain consistent hormone levels. Specific instructions for managing travel or time zones can be reviewed with a healthcare professional.


Q: Do any official warnings exist about using Activella for longer than five years?

Official prescribing principles mandate using the lowest effective dose for the shortest duration consistent with treatment goals. Clinical studies supporting the primary benefits for hot flashes and vaginal atrophy were generally short-term, meaning long-term safety and efficacy beyond a few years are less established in these specific trials.


Q: What is the typical timeframe before a follow-up appointment is needed after starting Activella?

The need for continued therapy must be periodically re-evaluated by a healthcare professional. Although there is no fixed rule, clinical guidelines often suggest a follow-up assessment within the first few months (e.g., 3–6 months) to assess the initial response and address any necessary adjustments to the regimen.


Q: Can a history of migraines affect eligibility for Activella?

While not listed as an absolute prohibition, a known history of migraines, particularly those with aura, is a clinical risk factor. This requires a healthcare provider’s careful evaluation for eligibility due to the known increased risk of stroke associated with all estrogen-containing therapies.


Q: Does grape juice or grapefruit interact with Activella?

Official product information describes that grapefruit or grapefruit juice can interfere with the liver enzymes that process the medication. This interference can potentially lead to increased levels of the drug in the body and increase the risk for side effects.


Q: Are there any known effects of Activella on vision?

Regulatory warnings describe that sudden partial or complete loss of vision is a condition that warrants immediate cessation of the medication. Official information describes that patients who wear contact lenses and notice visual changes or discomfort may need further evaluation by a healthcare provider.


Q: How does Activella compare generally to patch or cream forms of hormone therapy?

Activella is an oral tablet that delivers hormones systemically (through the entire body). Transdermal patches or vaginal creams are alternative delivery methods that are processed by the body differently than oral tablets, resulting in different pharmacokinetic profiles (how the hormones are absorbed and distributed).


Q: Can women with a family history of breast cancer use Activella?

A personal history of breast cancer is listed in official documentation as an absolute prohibition for use. While a family history is not explicitly listed as a contraindication, official information describes it as an important risk factor that a healthcare provider typically assesses before prescribing HRT.

How should Activella be stored and disposed of?

How to Store and Dispose of Activella

The required storage conditions for Activella tablets are defined by regulatory labeling to ensure product stability.


Official Storage and Handling

Activella must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept from freezing and protected from degradation factors, including excessive heat, moisture, and direct light. Tablets must remain in the tightly closed, original container.

As a safety measure, the medication must be stored out of the sight and reach of children.


Disposal Requirements

Expired or unused Activella tablets must be disposed of according to local guidelines, often through an official drug take-back program. When such programs are unavailable, disposal into household trash is permitted only after mixing the medicine with an undesirable substance (such as used coffee grounds or cat litter) and sealing it in a container. The medicine must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Activella found in:

A-Z Index: